CompanyGraph
Clarity Pharmaceuticals Ltd
CU6 · ASX · Australia
Price data from its CU6 listing on CXA
claritypharmaceuticals.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.39M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
757.35MAUD531.78M · vs all stocks (USD)
Revenue (TTM)
10.53MAUD7.39M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.18xvs all stocks
52-Week Change
-41.15%vs all stocks
Market Capitalization
757.35MAUD531.78M · vs all stocks (USD)
Enterprise Value
608.72MAUD427.41M · vs all stocks (USD)
Forward P/E
-7.72xvs Biotechnology peers
Price to Sales (TTM)
72.83xvs Biotechnology peers
Price to Book (MRQ)
4.12xvs Biotechnology peers
Enterprise to Revenue
57.83xvs Biotechnology peers
Enterprise to EBITDA
-5.63xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1095.64%vs Biotechnology peers
Return on Assets (TTM)
-45.12%vs Biotechnology peers
Return on Equity (TTM)
-77.55%vs Biotechnology peers
Revenue (TTM)
10.53MAUD7.39M · vs all stocks (USD)
Revenue per Share (TTM)
0.0290AUDUpdated Sep 29, 2026Quarterly Revenue Growth
-1.10%vs Biotechnology peers
Gross Profit (TTM)
10.53MAUD7.39M · vs all stocks (USD)
EBITDA (TTM)
-108.10MAUD-75.90M · vs all stocks (USD)
Net Income (TTM)
-107.14MAUD-75.23M · vs all stocks (USD)
Operating Cash Flow (TTM)
-92.55MAUD-64.98M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-59.44MAUD-41.73M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00AUDUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Operating Income
-78.56MAUD-55.16M · vs all stocks (USD)
Pre-tax Income
-63.88MAUDFY2025 · Jun 30, 2025Income Tax Expense
416.51KAUDFY2025 · Jun 30, 2025Net Income
-64.30MAUDFY2025 · Jun 30, 2025EBIT
-78.56MAUDFY2025 · Jun 30, 2025EBITDA (Income Statement)
-78.37MAUDFY2025 · Jun 30, 2025Research & Development
66.88MAUDFY2025 · Jun 30, 2025Selling, General & Administrative
6.18MAUDFY2025 · Jun 30, 2025Other Operating Expenses
5.32MAUDFY2025 · Jun 30, 2025Non-operating Interest Income
4.76MAUDFY2025 · Jun 30, 2025EPS (Basic)
-0.2010AUDFY2025 · Jun 30, 2025EPS (Diluted)
-0.2010AUDFY2025 · Jun 30, 2025Basic Shares Outstanding
319.20MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
319.20MSharesFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
47.68MAUDFY2025 · Jun 30, 2025Income Tax Paid
719.25KAUDFY2025 · Jun 30, 2025Capital Expenditures
-182.74KAUDFY2025 · Jun 30, 2025Sale of Investments
52.17MAUDFY2025 · Jun 30, 2025Net Investing Cash Flow
51.99MAUDFY2025 · Jun 30, 2025Common Stock Repurchase
-193.39KAUDFY2025 · Jun 30, 2025Net Financing Cash Flow
2.21MAUDFY2025 · Jun 30, 2025Shares Outstanding
321.47MSharesUpdated Sep 29, 2026Float Shares
292.75MSharesUpdated Sep 29, 2026% Held by Insiders
21.15%vs all stocks
% Held by Institutions
26.64%vs all stocks
Total Cash (MRQ)
178.25MAUD125.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4780AUDUpdated Sep 29, 2026Total Debt (MRQ)
0.00AUDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
16.09xvs Biotechnology peers
Book Value per Share (MRQ)
0.4990AUDUpdated Sep 29, 2026Total Assets
101.17MAUD71.04M · vs all stocks (USD)
Total Current Assets
100.61MAUDFY2025 · Jun 30, 2025Total Liabilities
10.94MAUDFY2025 · Jun 30, 2025Total Non-current Assets
566.00KAUDFY2025 · Jun 30, 2025Total Non-current Liabilities
561.75KAUDFY2025 · Jun 30, 2025Total Current Liabilities
10.38MAUDFY2025 · Jun 30, 2025Cash
18.28MAUDFY2025 · Jun 30, 2025Cash Equivalents
29.41MAUDFY2025 · Jun 30, 2025Cash & Cash Equivalents
47.68MAUDFY2025 · Jun 30, 2025Other Short-term Investments
36.43MAUDFY2025 · Jun 30, 2025Accounts Payable
3.21MAUDFY2025 · Jun 30, 2025Common Stock (Book)
255.89MAUDFY2025 · Jun 30, 2025Retained Earnings
-176.99MAUDFY2025 · Jun 30, 2025Total Shareholders' Equity
90.23MAUD63.36M · vs all stocks (USD)
52-Week Low
1.80AUDUpdated Sep 29, 202652-Week High
5.87AUDUpdated Sep 29, 202652-Week Change
-41.15%vs all stocks
Beta
1.18xvs all stocks
50-Day MA
2.38AUDUpdated Sep 29, 2026200-Day MA
2.84AUDUpdated Sep 29, 2026Avg 10-Day Volume
1.53MSharesUpdated Sep 29, 2026Avg 30-Day Volume
1.78MSharesUpdated Sep 29, 2026Diluted EPS (TTM)
-0.2900AUDUpdated Sep 29, 2026Other Income / Expense
9.92MAUDFY2025 · Jun 30, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.39M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,391,066.12Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eupraxia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cerus Corporation
Tier 1ProductionApproval-Gated PipelineRule
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface